Loading AI tools
American biotech company From Wikipedia, the free encyclopedia
Delix Therapeutics is an American biotech company based in Boston, Massachusetts.[1] The company develops novel neuroplasticity-promoting therapeutics for central nervous system (CNS) diseases such as depression and post-traumatic stress disorder (PTSD).[2] It was co-founded in 2019 by David E. Olson and Nick Haft.[3]
Company type | Private |
---|---|
Industry | |
Founded | 2019 |
Headquarters | Boston, Massachusetts |
Key people | Mark Rus (Chief Executive Officer) |
Website | delixtherapeutics |
The company was founded to develop novel, non-hallucinogenic psychoplastogens, also known as neuroplastogens, to better treat mental health disorders at scale. David E. Olson founded the company following his discovery that psychedelics are highly potent neuroplasticity-promoting compounds.[2] In September 2021, Delix secured a Series A financing round, the largest in the space, to continue their work focused on neuroplastogens and neuroplasticity therapeutics.[4] Also in Fall of 2021, Delix joined the National Institute on Drug Abuse industry partnering program to screen psychoplastogens in models of substance use disorder.[2] In 2021, the company expanded the leadership team, adding a new CEO,[5] CSO,[1] and CMO[1]
In 2021, Delix was named one of the Fierce 15 of Biotech.[6] In 2022, Nature named Delix Spinout of the Year[7] and Delix was awarded the Healthcare Businesswomen's Association (HBA) ACE award.[8] In 2023, Delix was a finalist for the Prix Galien award for Best Startup[9] and the BWB award for Biotech Innovation of the Year[10] and won the Biotech Breakthrough Award for Neuroscience Therapeutics Company of the Year.[11]
To date, the company has synthesized over 2000 novel psychoplastogens.[12] Many of these small molecule compounds are analogs of known psychedelics such as ibogaine and 5-MeO-DMT.[13] Delix focuses on the development of non-hallucinogenic psychoplastogens as scalable alternatives to first-generation hallucinogenic psychoplastogens like ketamine and psilocybin.[14] Their compounds have been engineered to lack cardiotoxicity and psychostimulant properties characteristic of other first-generation psychoplastogens.[15] Two of the company’s known assets are tabernanthalog and AAZ-A-154.[16] Delix has licensed these compounds from UC Davis.[17]
Seamless Wikipedia browsing. On steroids.
Every time you click a link to Wikipedia, Wiktionary or Wikiquote in your browser's search results, it will show the modern Wikiwand interface.
Wikiwand extension is a five stars, simple, with minimum permission required to keep your browsing private, safe and transparent.